BMY Bristol-Myers Squibb
- 43.990
- +0.290+0.66%
- 43.990
- 0.0000.00%
Bristol-Myers Squibb News
8-K: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
DEFA14A: Others
Bristol-Myers Squibb | DEFA14A: Others
Bristol-Myers Squibb | DEF 14A: Definitive information statements
Bristol-Myers Squibb | 8-K: Gerald Storch Will Not Run for Re-Election to the Board of Directors
Bristol-Myers Squibb | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Bristol-Myers Squibb | 8-K: Bristol-Myers Squibb Announces Completion of Acquisition of Karuna Therapeutics
Bristol-Myers Squibb | 8-K: Collection of Recent Notes Public Offering Announcements
Bristol-Myers Squibb | 8-K: Bristol-Myers Squibb Appoints Phil Holzer as Senior Vice President and Chief Financial Officer of the Company
Bristol-Myers Squibb | 8-K: Bristol Myers Squibb Recommends Stockholders Reject Mini-Tender Offer by Tutanota LLC
Bristol-Myers Squibb | 8-K: Bristol-Myers Squibb Announces Fourth Quarter and Full Year 2023 Financial Results
Bristol-Myers Squibb | 8-K: Investor presentation of J.P. Morgan Healthcare Conference
Bristol-Myers Squibb | DFAN14A: Definitive additional proxy soliciting materials filed by non-management
Bristol-Myers Squibb | DFAN14A: Definitive additional proxy soliciting materials filed by non-management
Bristol-Myers Squibb | 8-K: Bristol-Myers Squibb Have Signed an Agreement and Plan of Merger
Bristol-Myers Squibb | 8-K: Current report
Bristol-Myers Squibb | 8-K/A: Officers Management Change(Amendment)
Bristol-Myers Squibb | 8-K: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Bristol-Myers Squibb | DFAN14A: Definitive additional proxy soliciting materials filed by non-management
Bristol-Myers Squibb | 8-K: Entry into Accelerated Share Repurchase Agreement
Analysis
Price Target
No Data
